Table 1 Baseline characteristics in HCAP patients treated with vancomycin or linezolid

Patients, n

1211

265

946

N/A

Year of hospitalization, n (%)

 2001–2004

541 (44.7)

153 (57.7)

388 (41.0)

<0.0001

 2005–2007

670 (55.3)

112 (42.3)

558 (59.0)

Age (years), median (IQR)

76 (70–80)

76 (70–80)

76 (70–81)

0.892

Male, n (%)

1189 (98.2)

259 (97.7)

930 (98.3)

0.537

Race, n (%)

 White

961 (79.4)

225 (84.9)

736 (77.8)

0.033

 Black

188 (15.5)

32 (12.1)

156 (16.5)

 Other

62 (5.1)

8 (3.0)

54 (5.7)

Hispanic ethnicity, n (%)

159 (13.1)

10 (3.8)

149 (15.7)

<0.0001

VHA priority group, n (%)

 1

280 (23.1)

45 (17.0)

235 (24.8)

0.019

 2–6

859 (70.9)

200 (75.5)

659 (69.7)

 7–8

72 (6.0)

20 (7.5)

52 (5.5)

HCAP risk factors, n (%)

 Hospitalization within 90 days

941 (77.7)

191 (72.1)

750 (79.3)

0.013

 Nursing home resident within 90 days

36 (3.0)

7 (2.6)

29 (3.1)

0.719

 Hemodialysis

514 (42.4)

112 (42.3)

402 (42.5)

0.947

 Outpatient IV antibiotics within 90 days

152 (12.6)

22 (8.3)

130 (13.7)

0.018

>1 HCAP risk factor, n (%)

384 (31.1)

62 (23.4)

322 (34.0)

0.001

Charlson comorbidity score, median (IQR)

4 (2–6)

4 (2.5–5.5)

4 (2-6)

0.233

Comorbid conditions, n (%)

 Myocardial infarction

121 (10.0)

34 (12.8)

87 (9.2)

0.081

 Heart failure

381 (31.5)

103 (38.8)

278 (29.4)

0.003

 Cerebrovascular disease

302 (24.9)

59 (22.3)

243 (25.7)

0.255

 Chronic obstructive pulmonary disease

614 (50.7)

164 (61.9)

450 (47.6)

<0.0001

 Liver disease

16 (1.3)

1 (0.4)

15 (1.6)

0.128

 Chronic kidney disease

523 (43.2)

114 (43.0)

409 (43.2)

0.950

 Diabetes

442 (41.6)

90 (39.0)

352 (42.2)

0.376

 Neoplastic disease

433 (35.8)

92 (34.7)

341 (36.0)

0.690

 HIV/AIDS

4 (0.3)

1 (0.4)

3 (0.3)

0.880

Substance abuse or dependence, n (%)

 Tobacco use

401 (33.1)

100 (37.7)

301 (31.8)

0.070

 Alcohol abuse or dependence

49 (4.0)

11 (4.2)

38 (4.0)

0.922

Medication use within 90 days, n (%)

 Cardiovascular medications

796 (65.7)

196 (74.0)

600 (63.4)

0.001

 Anti-diabetic medications

309 (25.5)

78 (29.4)

231 (24.4)

0.098

 Inhaled corticosteroids

236 (19.5)

67 (25.3)

169 (17.9)

0.007

 Systemic corticosteroids

321 (26.5)

87 (32.8)

234 (24.7)

0.008

 Pulmonary medications

431 (35.6)

123 (46.4)

308 (32.6)

<0.0001

Noninvasive mechanical ventilation, n (%)

24 (2.0)

3 (1.1)

21 (2.2)

0.262

Organ failure, n (%)

266 (22.0)

45 (17.0)

221 (23.4)

0.027

Pathogens with a prevalence ≥1 %, n (%)

 Staphylococcus aureus

87 (7.2)

4 (1.5)

83 (8.8)

0.019

 Methicillin-resistant S. aureus

66 (5.5)

5 (1.9)

61 (5.0)

0.004

 Streptococcus pneumoniae

32 (2.6)

8 (3.0)

24 (2.5)

0.005

 Pseudomonas

55 (4.5)

7 (2.6)

48 (5.1)

0.569

 Klebsiella pneumoniae

16 (1.3)

0 (0.0)

16 (1.7)

0.152